“We hypothesized that the prevalence of obesity would be higher in cannabis users than in nonusers… this analysis showed that even if cannabis consumption increases appetite, people using cannabis are less likely to be obese than people who do not use cannabis…
The authors conclude that the prevalence of obesity is lower in cannabis users than in nonusers.”
http://www.ncbi.nlm.nih.gov/pubmed/21868374
http://aje.oxfordjournals.org/content/174/8/929.long
“We estimated the association between legalizing medical marijuana and suicides.
Suicides among men aged 20 through 39 years fell after medical marijuana legalization compared with those in states that did not legalize.
The negative relationship between legalization and suicides among young men is consistent with the hypothesis that marijuana can be used to cope with stressful life events.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232164/
http://www.ncbi.nlm.nih.gov/pubmed/24432945
http://ajph.aphapublications.org/doi/10.2105/AJPH.2013.301612
“In this article, real-life data from clinical practice showing specific aspects relating to use of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) in patients with moderate to severe spasticity resistant to usual therapy will be presented…
These case reports highlight the diverse nature of the MS spasticity population and they show the possible usefulness of THC:CBD oromucosal spray in individual patients with moderate to severe spasticity resistant to existing therapies…
Perhaps the most important finding is the possibility of obtaining relevant improvements in QoL/ADL (quality of life/activities of daily living) in some patients with resistant MS spasticity, allowing them to engage back in physical and social activities.”
“New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®)…
A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes…
THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity…
Findings to date reinforce the efficacy and safety observed in Phase III clinical trials…
Importantly, no additional safety concerns were identified…
Thus, these new data support a positive benefit-risk relationship for THC:CBD oromucosal spray during longer-term use.”
“Endocannabinoids (eCB) have been functionally linked to cocaine’s rewarding effects.
…changes in CB1r function – alone and in combination with cocaine – affected stereotyped vigilance-related behaviors… further implicating the eCB system in the neurobiological mechanisms of cocaine addiction.”
“Experimental in vitro and in vivo evidence, as well as results of clinical studies, have indicated that molecular targets for medications currently available for the treatment of mood disorders, sexually transmitted diseases, metabolic disorders, and diabetes may be active and relevant in thyroid cancer.
For instance, the derivatives of cannabis and an anti-diabetic agent, metformin, are both able to inhibit extracellular signal-regulated protein kinase (ERK), which is commonly activated in thyroid cancer cells.
We present here several examples of well-known medications that have the potential to become new therapeutics for patients with thyroid cancer. Repositioning of established medications for the treatment of thyroid cancer could broaden the scope of current therapeutic strategies. These diverse treatment choices could allow physicians to provide an individualized approach to optimize treatment for patients with thyroid cancer.”
“Forty samples were extracted from defatted kernels and hulls of two varieties of hempseed (Bama and Yunma No. 1)…
Two compounds, with predominant antiradical activity, were isolated…
N-trans-caffeoyltyramine and cannabisin B….
The two compounds exhibited significant high DPPH() scavenging activity and protective effect against in vitro oxidation of human low-density lipoprotein compared with extracts from flaxseed, grape seed, and soybean.
This suggests that hempseed hull extract is a potential source of natural antioxidants, which could be added to dietary supplements to help prevent oxidative stress.”
“Cannabinoid type 1 Receptor (CB1) belongs to the GPCR family and it has been targeted, so far, for the discovery of drugs aimed at the treatment of neuropathic pain, nausea, vomit, and food intake disorders. Here, we present the development of the first fluorescent assay enabling the measurement of kinetic binding constants for CB1orthosteric ligands…
…a sustainable valid alternative to the expensive and environmental impacting radiodisplacement techniques and paves the way for an easy, fast and cheap high-throughput drug screening toward CB1 for identification of new orthosteric and allosteric modulators.”
“Recent studies have suggested immunomodulatory and anti-inflammatory effects of cannabinoid receptor 2 (CB2R) activation, which shows no psychoactivity…
These data suggest that CB2R may be a potential therapeutic target of RA.”
“Type-1 cannabinoid receptors (CB1R) are important regulators of the neurodegenerative damage in multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis (EAE). In GABAergic striatal neurons, CB1R stimulation exerts protective effects by limiting inflammation…
Our results provide further evidence that CB1R are involved in EAE pathophysiology, and suggest that both pre- and postsynaptic alterations of glutamate transmission are important to drive excitotoxic neurodegeneration typical of this disorder.”